Insider Selling: Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) General Counsel Sells $15,333.75 in Stock

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) General Counsel Martin Wilson sold 1,175 shares of Rocket Pharmaceuticals stock in a transaction that occurred on Thursday, November 21st. The shares were sold at an average price of $13.05, for a total transaction of $15,333.75. Following the sale, the general counsel now owns 63,560 shares of the company’s stock, valued at approximately $829,458. The trade was a 1.82 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Rocket Pharmaceuticals Stock Performance

Shares of RCKT opened at $14.20 on Thursday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 6.05 and a current ratio of 6.05. Rocket Pharmaceuticals, Inc. has a 1 year low of $12.62 and a 1 year high of $32.53. The firm has a fifty day moving average of $16.89 and a 200-day moving average of $19.70. The company has a market cap of $1.29 billion, a price-to-earnings ratio of -5.13 and a beta of 1.09.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Leerink Partners reduced their price target on shares of Rocket Pharmaceuticals from $46.00 to $44.00 and set an “outperform” rating on the stock in a report on Tuesday, November 19th. Chardan Capital reiterated a “buy” rating and set a $62.00 price objective on shares of Rocket Pharmaceuticals in a research report on Monday, November 18th. JPMorgan Chase & Co. raised their target price on shares of Rocket Pharmaceuticals from $50.00 to $54.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 6th. Canaccord Genuity Group reiterated a “buy” rating and issued a $39.00 price target on shares of Rocket Pharmaceuticals in a report on Tuesday, November 19th. Finally, Scotiabank assumed coverage on Rocket Pharmaceuticals in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $50.00 price objective for the company. One research analyst has rated the stock with a sell rating, one has given a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $51.00.

Institutional Trading of Rocket Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the business. Nisa Investment Advisors LLC increased its holdings in shares of Rocket Pharmaceuticals by 31.9% during the second quarter. Nisa Investment Advisors LLC now owns 3,160 shares of the biotechnology company’s stock valued at $68,000 after purchasing an additional 764 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in Rocket Pharmaceuticals by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,292 shares of the biotechnology company’s stock valued at $61,000 after buying an additional 582 shares in the last quarter. Values First Advisors Inc. acquired a new position in Rocket Pharmaceuticals during the 3rd quarter valued at about $108,000. SG Americas Securities LLC acquired a new stake in shares of Rocket Pharmaceuticals in the 3rd quarter worth approximately $113,000. Finally, Dana Investment Advisors Inc. lifted its stake in shares of Rocket Pharmaceuticals by 4.4% in the 2nd quarter. Dana Investment Advisors Inc. now owns 13,847 shares of the biotechnology company’s stock worth $298,000 after acquiring an additional 586 shares during the period. 98.39% of the stock is currently owned by institutional investors and hedge funds.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.